An N-Fluorinated Imide for Practical Catalytic Imidations
Catalytic imidation using NFSI as the nitrogen source has become an emerging tool for oxidative carbon-nitrogen bond formation. However, the less than ideal benzenesulfonimide moiety is incorporated into products, severely detracting its synthetic value.
THIOPHENE-2-CARBOXAMIDE DERIVATIVES AS MODULATORS OF CCR9 RECEPTOR
Provided are compounds of Formula (I) or of Formula (II) that are modulators of CCR9 receptor activity, compositions containing the compounds and methods of use of the compounds and compositions. In certain embodiments, provided are methods for treating or amelioratin diseases associated with modulation of CCR9 receptor activity.
-
Page/Page column 42-43
(2009/05/29)
Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors
Novel N9-arenethenyl purines, optimized potent dual Src/Abl tyrosine kinase inhibitors, are described. The key structural feature is a trans vinyl linkage at N9 on the purine core which projects hydrophobic substituents into the sele
Wang, Yihan,Shakespeare, William C.,Huang, Wei-Sheng,Sundaramoorthi, Raji,Lentini, Scott,Das, Sasmita,Liu, Shuangying,Banda, Geeta,Wen, David,Zhu, Xiaotian,Xu, Qihong,Keats, Jeffrey,Wang, Frank,Wardwell, Scott,Ning, Yaoyu,Snodgrass, Joseph T.,Broudy, Mark I.,Russian, Karin,Dalgarno, David,Clackson, Tim,Sawyer, Tomi K.
scheme or table
p. 4907 - 4912
(2009/05/30)
UNSATURATED HETEROCYCLIC DERIVATIVES
This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.
-
Page/Page column 42
(2008/06/13)
Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists
The present invention relates to urotensin II receptor antagonists, CCR-9 antagonists, pharmaceutical compositions containing them and their use.
-
(2008/06/13)
More Articles about upstream products of 66314-77-0